Centro Studi GISED


Go to content
Change language  EN IT

RegiSCAR

What we do

Regiscar

The RegiSCAR project is an international research program supported by the European Union (contract n. QLG1-CT-2002-01738) collecting cases of severe adverse reactions to drugs at an European level and evaluating the role of polymorphisms in several candidate genes as risk factors for the reactions. Centro Studi GISED coordinated the project in Italy.

Results

Results of the study were published by several scientific journals:

Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071-80.

Sekula P, Dunant A, Mockenhaupt M, et al; RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133:1197-204.

Lee HY, Dunant A, Sekula P, et al. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol. 2012;167:555-62.

Tang YH, Mockenhaupt M, Henry A, et al. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. Clin Exp Allergy. 2012;42:248-54.

Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011;32:237-45.

Lonjou C, Borot N, Sekula P, et al.; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99-107.

Back to research project


Last update oct 4 2021  -  Centro Studi GISED  P.I. 02274270988 | Terms of use    Privacy    Credits

Back to content | Back to main menu
Facebook Twitter LinkedIn Email